Recovery

Of the four platforms, Recovery is the one accumulating the most translational momentum in 2026. Tissue-bioengineering groups are publishing combinatorial work on collagen fragments, thymosin-β4-derived peptides and growth-factor mimetic sequences (PDGF, VEGF, FGF) in high-impact journals. Much of that work is preclinical — cell lines, organoids, animal models — but the catalog of molecules with a plausible mechanism backed by literature has roughly doubled compared with 2020.

The consequence for the lab looking to purchase is ambiguous: there are more options but also more noise. The difference between a genuinely characterized peptide and one with circumstantial data is hard to read from a sales page. The Recovery platform exists to cut from that universe the families best characterized in purity and reproducibility — not the ones most searched on social media. If a molecule does not have a stabilized analytical method and a batch reference, it does not enter the platform.

We are currently validating candidates: BPC-157 analogs with a controlled degradation profile, elastin-derived peptides with in-vitro healing activity, and optimized TB-500 sequences (the active fragment of thymosin-β4). The plan is to release ONE at a time, each with its full technical material, lot number, CoA and bibliographic reference — not to flood the catalog with half-characterized molecules. That is why the platform is not yet open.